Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer.

ABSTRACT:

Background

Docetaxel is the first-line chemotherapy for castration-resistant prostate cancer (CRPC). However, response rates are ∼50% and determined quite late in the treatment schedule, thus non-responders are subjected to unnecessary toxicity. The potential of circulating microRNAs as early biomarkers of docetaxel response in CRPC patients was investigated in this study.

Methods

Global microRNA profiling was performed on docetaxel-resistant and sensitive cell lines to identify candidate circulating microRNA biomarkers. Custom Taqman Array MicroRNA cards were used to measure the levels of 46 candidate microRNAs in plasma/serum samples, collected before and after docetaxel treatment, from 97 CRPC patients.

Results

Fourteen microRNAs were associated with serum prostate

SUBMITTER: Lin HM 

PROVIDER: S-EPMC4021524 | biostudies-literature | 2014 May

REPOSITORIES: biostudies-literature